| Indicators | Browse All

Korro Bio, Inc. (KRRO)

Healthcare | Biotechnology | Cambridge, United States | NasdaqCM
12.91 USD -0.35 (-2.640%) ⇩ (Aug. 28, 2026, 4 p.m. EDT)
After hours: 12.91

Short-term:★★☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | Aug. 22, 2026, 4:52 a.m. EDT

The investment case here is structurally broken. While the balance sheet currently shows a fortress-like liquidity position with a current ratio of 9.5x and manageable debt, this is a temporary reprieve for a business that has delivered a catastrophic -98% return over the last five years. The market has already priced in a permanent impairment of value; the stock trades at a massive premium to sales despite generating zero revenue and burning cash aggressively. The recent price action is merely a technical bounce off multi-year lows, not a sign of recovery. Crucially, insider selling by the CEO and the failure of a key study (AATD) confirm that the core value drivers are evaporating. With no dividend to cushion the blow and a multi-year trajectory of destruction, this is a capital preservation play to stay away, not a buy.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.083162
AutoETS0.096748
AutoARIMA0.105143
AutoTheta0.105794

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 39%
H-stat 0.36
Ljung-Box p 0.000
Jarque-Bera p 0.194
Excess Kurtosis -0.51
Attribute Value
Sector Healthcare
Debt to Equity Ratio 40.894
Revenue per Share 0.198
Market Cap 190,108,080
Forward P/E -2.90
Beta 2.21
Website https://www.korrobio.com

As of Aug. 22, 2026, 4:52 a.m. EDT: Speculators are positioning for a significant downside event rather than a rally. Put open interest is heavily concentrated deep out-of-the-money (strikes at $2.50 and $7.50), suggesting a 'crash' thesis or a bet on a failed clinical trial. Conversely, call activity is sparse and skewed toward lower strikes ($10-$15), with virtually no speculative volume at higher targets ($35+). The implied volatility on deep puts is elevated relative to calls, reinforcing a bearish sentiment.


Info Dump

Attribute Value
52 Week Change -0.40283722
Address1 60 First Street
Address2 2nd Floor Suite 250
All Time High 2,918.5
All Time Low 5.204
Ask 12.98
Ask Size 2
Audit Risk 8
Average Analyst Rating 1.4 - Strong Buy
Average Daily Volume10 Day 68,690
Average Daily Volume3 Month 181,985
Average Volume 181,985
Average Volume10Days 68,690
Beta 2.213
Bid 9.51
Bid Size 2
Board Risk 10
Book Value 7.019
City Cambridge
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 9
Country United States
Crypto Tradeable 0
Currency USD
Current Price 12.91
Current Ratio 9.553
Custom Price Alert Confidence HIGH
Date Short Interest 1,786,665,600
Day High 13.42
Day Low 12.8
Debt To Equity 40.894
Display Name Korro Bio
Earnings Timestamp 1,786,019,400
Earnings Timestamp End 1,794,486,600
Earnings Timestamp Start 1,794,486,600
Ebitda -74,326,000
Ebitda Margins 0.0
Enterprise To Ebitda -1.578
Enterprise To Revenue 49.238
Enterprise Value 117,285,088
Eps Current Year -5.178
Eps Forward -4.45889
Eps Trailing Twelve Months -9.62
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 12.7219
Fifty Day Average Change 0.18809986
Fifty Day Average Change Percent 0.014785516
Fifty Two Week Change Percent -40.283722
Fifty Two Week High 55.89
Fifty Two Week High Change -42.98
Fifty Two Week High Change Percent -0.76901054
Fifty Two Week Low 5.204
Fifty Two Week Low Change 7.706
Fifty Two Week Low Change Percent 1.4807839
Fifty Two Week Range 5.204 - 55.89
Financial Currency USD
First Trade Date Milliseconds 1,570,109,400,000
Float Shares 10,499,386
Forward Eps -4.45889
Forward P E -2.8953395
Free Cashflow -41,390,124
Full Exchange Name NasdaqCM
Full Time Employees 57
Fullday Change -0.35
Fullday Change Percent -2.63952
Fullday Price 12.91
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,785,542,400
Gross Margins 0.0
Gross Profits -41,024,000
Has Pre Post Market Data 1
Held Percent Insiders 0.00939
Held Percent Institutions 1.05223
Implied Shares Outstanding 14,725,646
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,699,228,800
Last Split Factor 1:50
Long Business Summary Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Long Name Korro Bio, Inc.
Market us_market
Market Cap 190,108,080
Market State CLOSED
Max Age 86,400
Message Board Id finmb_619256344
Most Recent Quarter 1,782,777,600
Net Income To Common -106,644,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 195,262,065
Number Of Analyst Opinions 10
Open 13.13
Operating Cashflow -67,948,000
Operating Margins -32.28338
Overall Risk 10
Payout Ratio 0.0
Phone 617 468 1999
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 12.91
Post Market Time 1,787,959,806
Previous Close 13.26
Price Eps Current Year -2.4932406
Price Hint 2
Price To Book 1.8392934
Price To Sales Trailing12 Months 79.81028
Profit Margins 0.0
Quick Ratio 9.11
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.36364
Region US
Regular Market Change -0.35
Regular Market Change Percent -2.63952
Regular Market Day High 13.42
Regular Market Day Low 12.8
Regular Market Day Range 12.8 - 13.42
Regular Market Open 13.13
Regular Market Previous Close 13.26
Regular Market Price 12.91
Regular Market Time 1,787,947,201
Regular Market Volume 67,367
Return On Assets -0.27953
Return On Equity -0.97691
Revenue Per Share 0.198
Sand P52 Week Change 0.20504117
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 7
Shares Outstanding 14,725,646
Shares Percent Shares Out 0.1027
Shares Short 1,511,713
Shares Short Previous Month Date 1,784,073,600
Shares Short Prior Month 1,459,180
Short Name Korro Bio, Inc.
Short Percent Of Float 0.115
Short Ratio 10.93
Source Interval 15
State MA
Symbol KRRO
Target High Price 30.0
Target Low Price 10.0
Target Mean Price 20.2
Target Median Price 21.5
Total Cash 115,036,000
Total Cash Per Share 7.812
Total Debt 42,213,000
Total Revenue 2,382,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -9.62
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 11.453625
Two Hundred Day Average Change 1.4563751
Two Hundred Day Average Change Percent 0.12715408
Type Disp Equity
Volume 67,367
Website https://www.korrobio.com
Zip 2,141